QTMAN

Summary

QTMAN (queuosine-tRNA mannosyltransferase, HGNC:20887) is a protein-coding gene on chromosome 2q22.3, encoding tRNA-queuosine alpha-mannosyltransferase (Q4AE62). Glycosyltransferase that specifically catalyzes mannosylation of cytoplasmic tRNA(Asp) modified with queuosine at position 34 (queuosine(34)).

Enables tRNA-queuosine(34) beta-mannosyltransferase activity. Involved in regulation of translation and tRNA modification. Located in nucleus. Is active in cytoplasm.

Source: NCBI Gene 79712 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 61 total — 5 pathogenic
• MANE Select transcript: NM_001376312

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20887
Approved symbol	QTMAN
Name	queuosine-tRNA mannosyltransferase
Location	2q22.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11753, Hmat-Xa
Ensembl gene	ENSG00000121964
Ensembl biotype	protein_coding
OMIM	610165
Entrez	79712

Gene structure

Transcript identifiers

Ensembl transcripts: 70 — 62 protein_coding, 5 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000241391, ENST00000344850, ENST00000392867, ENST00000392869, ENST00000392871, ENST00000409214, ENST00000409298, ENST00000415569, ENST00000417450, ENST00000429978, ENST00000437114, ENST00000463875, ENST00000467352, ENST00000476958, ENST00000482601, ENST00000482961, ENST00000484303, ENST00000491448, ENST00000542155, ENST00000618778, ENST00000682281, ENST00000909683, ENST00000909684, ENST00000909685, ENST00000909686, ENST00000909687, ENST00000909688, ENST00000909689, ENST00000909690, ENST00000909691, ENST00000909692, ENST00000909693, ENST00000909694, ENST00000909695, ENST00000909696, ENST00000909697, ENST00000909698, ENST00000909699, ENST00000909700, ENST00000909701, ENST00000909702, ENST00000909703, ENST00000909704, ENST00000909705, ENST00000909706, ENST00000909707, ENST00000909708, ENST00000909709, ENST00000909710, ENST00000909711, ENST00000927177, ENST00000970677, ENST00000970678, ENST00000970679, ENST00000970680, ENST00000970681, ENST00000970682, ENST00000970683, ENST00000970684, ENST00000970685, ENST00000970686, ENST00000970687, ENST00000970688, ENST00000970689, ENST00000970690, ENST00000970691, ENST00000970692, ENST00000970693, ENST00000970694, ENST00000970695

RefSeq mRNA: 45 — MANE Select: NM_001376312 NM_001006636, NM_001164629, NM_001284233, NM_001284234, NM_001284235, NM_001284238, NM_001354350, NM_001354351, NM_001354352, NM_001354353, NM_001354354, NM_001354355, NM_001354356, NM_001354358, NM_001354360, NM_001354361, NM_001354362, NM_001376306, NM_001376307, NM_001376308, NM_001376309, NM_001376310, NM_001376311, NM_001376312, NM_001376313, NM_001376314, NM_001376315, NM_001376316, NM_001376317, NM_001376318, NM_001376319, NM_001376320, NM_001376321, NM_001376322, NM_001376323, NM_001376324, NM_001376325, NM_001376326, NM_001376327, NM_001376328, NM_001376329, NM_001376330, NM_001376331, NM_001376332, NM_024659

CCDS: CCDS2185, CCDS33300, CCDS63029, CCDS74582, CCDS74583, CCDS86884

Canonical transcript exons

ENST00000682281 — 12 exons

Exon	Start	End
ENSE00001427596	144235676	144235737
ENSE00001428859	144211515	144211579
ENSE00003462813	143957195	143957339
ENSE00003548808	143951982	143952073
ENSE00003550835	143952773	143952843
ENSE00003608794	144007182	144007535
ENSE00003643796	143970653	143970762
ENSE00003673505	144145572	144145739
ENSE00003679156	144208603	144208804
ENSE00003706057	143938068	143947135
ENSE00003788524	144141882	144142055
ENSE00003920010	144332439	144332512

Expression profiles

Bgee: expression breadth ubiquitous, 268 present calls, max score 93.34.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6086 / max 108.5483, expressed in 1738 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
30908	4.8678	1535
30909	2.3183	1183
30906	1.1941	668
30907	0.2284	92

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	93.34	gold quality
adrenal tissue	UBERON:0018303	93.26	gold quality
sural nerve	UBERON:0015488	93.21	gold quality
postcentral gyrus	UBERON:0002581	92.45	gold quality
corpus callosum	UBERON:0002336	92.43	gold quality
parietal lobe	UBERON:0001872	91.12	gold quality
superior frontal gyrus	UBERON:0002661	90.99	gold quality
orbitofrontal cortex	UBERON:0004167	90.88	gold quality
Brodmann (1909) area 46	UBERON:0006483	90.88	gold quality
colonic epithelium	UBERON:0000397	90.55	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.55	gold quality
calcaneal tendon	UBERON:0003701	90.39	gold quality
tendon	UBERON:0000043	90.08	gold quality
tibial nerve	UBERON:0001323	90.07	gold quality
prefrontal cortex	UBERON:0000451	89.95	gold quality
monocyte	CL:0000576	89.77	gold quality
ganglionic eminence	UBERON:0004023	89.63	gold quality
mononuclear cell	CL:0000842	89.62	gold quality
spinal cord	UBERON:0002240	89.53	gold quality
anterior cingulate cortex	UBERON:0009835	89.46	gold quality
cingulate cortex	UBERON:0003027	89.43	gold quality
leukocyte	CL:0000738	89.23	gold quality
tendon of biceps brachii	UBERON:0008188	89.23	gold quality
frontal cortex	UBERON:0001870	89.18	gold quality
neocortex	UBERON:0001950	89.11	gold quality
medial globus pallidus	UBERON:0002477	88.89	gold quality
amygdala	UBERON:0001876	88.88	gold quality
cerebral cortex	UBERON:0000956	88.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.68	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.68	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ENAD-17	no	250.63
E-ANND-3	no	6.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

93 targeting QTMAN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-875-3P	99.63	69.47	2548

Literature-anchored findings (GeneRIF, showing 4)

• relatively high expression level in the adult lung, spleen, testis, and peripheral blood leukocyte. (PMID:15068588)
• The elevated expression of the Hmat-Xa gene (GTDC1) might serve as a candidate marker for colon adenocarcinoma. (PMID:21821951)
• By deriving iPSCs from this patient and differentiating them into neural progenitor cells (NPCs) and neurons we dissected the disease process at the cellular level and observed defects in both NPCs and neuronal cells. We also showed that disruption of GTDC1 expression in wild type human NPCs and neurons showed a similar phenotype as patient’s iPSCs (PMID:28365779)
• Genomewide linkage scan by a targeted, high-density association scan for genetic variants enhancing persistently negative tuberculin skin test (PTST) in two independent Ugandan tuberculosis household cohorts. Association found with SNPs in neighboring genes ZEB2 and GTDC1 supported by both samples. Bioinformatic analysis suggests these variants may affect PTST- by regulating the histone deacetylase pathway. (PMID:30100616)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gtdc1	ENSDARG00000020642
mus_musculus	Gtdc1	ENSMUSG00000036890
rattus_norvegicus	Gtdc1	ENSRNOG00000031038
drosophila_melanogaster	CG15914	FBGN0030700

Protein

Protein identifiers

tRNA-queuosine alpha-mannosyltransferase — Q4AE62 (reviewed: Q4AE62)

Alternative names: Glycosyltransferase-like domain-containing protein 1, Mannosyltransferase-like protein Xa, Mat-Xa

All UniProt accessions (5): B8ZZ45, C9J2C5, C9JIH3, Q4AE62, F2Z2V8

UniProt curated annotations — full annotation on UniProt →

Function. Glycosyltransferase that specifically catalyzes mannosylation of cytoplasmic tRNA(Asp) modified with queuosine at position 34 (queuosine(34)). Mannosylates the cyclopentene moiety of queuosine(34) in tRNA(Asp) to form mannosyl-queuosine(34). Mannosylation of queuosine(34) in tRNA(Asp) is required to slow-down elongation at cognate codons, GAC and GAU, thereby regulating protein translation.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Ubiquitous. Expressed at high levels in the lung, brain, spleen, testis, placenta. ovary, pancreas, spleen and peripheral blood leukocytes. Expressed at low level in the colon, small intestine, kidney, skeletal muscle and thymus. Expressed at high level in colon adenocarcinoma.

Similarity. Belongs to the glycosyltransferase group 1 family. Glycosyltransferase 4 subfamily.

Isoforms (6)

UniProt ID	Names	Canonical?
Q4AE62-1	1	yes
Q4AE62-2	2
Q4AE62-3	3
Q4AE62-4	4, c
Q4AE62-5	5, f
Q4AE62-6	6, d

RefSeq proteins (45): NP_001006637, NP_001158101, NP_001271162, NP_001271163, NP_001271164, NP_001271167, NP_001341279, NP_001341280, NP_001341281, NP_001341282, NP_001341283, NP_001341284, NP_001341285, NP_001341287, NP_001341289, NP_001341290, NP_001341291, NP_001363235, NP_001363236, NP_001363237, NP_001363238, NP_001363239, NP_001363240, NP_001363241, NP_001363242, NP_001363243, NP_001363244, NP_001363245, NP_001363246, NP_001363247, NP_001363248, NP_001363249, NP_001363250, NP_001363251, NP_001363252, NP_001363253, NP_001363254, NP_001363255, NP_001363256, NP_001363257, NP_001363258, NP_001363259, NP_001363260, NP_001363261, NP_078935 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001296	Glyco_trans_1	Domain
IPR022701	QTMAN_N	Domain
IPR051862	GT-like_domain_containing_1	Family

Pfam: PF00534, PF12038

Catalyzed reactions (Rhea), 1 shown:

• queuosine(34) in tRNA(Asp) + GDP-alpha-D-mannose = O-4’’-alpha-D-mannosylqueuosine(34) in tRNA(Asp) + GDP + H(+) (RHEA:12885)

UniProt features (10 total): splice variant 6, chain 1, region of interest 1, compositionally biased region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q4AE62-F1	83.04	0.73

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 182 (showing top): AGGAAGC_MIR5163P, GOBP_TRNA_METABOLIC_PROCESS, TAL1ALPHAE47_01, ACTGCAG_MIR173P, CHANDRAN_METASTASIS_DN, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOBP_RNA_MODIFICATION, chr2q22, ATTCTTT_MIR186, MYOD_Q6, TCCAGAG_MIR518C, CCAGGTT_MIR490, CTTTGTA_MIR524, GOBP_TRNA_PROCESSING

GO Biological Process (3): tRNA wobble guanine modification (GO:0002099), tRNA modification (GO:0006400), regulation of translation (GO:0006417)

GO Molecular Function (3): tRNA-queuosine(34) beta-mannosyltransferase activity (GO:0016438), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
tRNA wobble base modification	1
tRNA processing	1
RNA modification	1
translation	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
mannosyltransferase activity	1
catalytic activity, acting on a tRNA	1
catalytic activity	1
transferase activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

678 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
QTMAN	ARHGAP15	Q53QZ3	716
QTMAN	KYNU	Q16719	523
QTMAN	LYPD6B	Q8NI32	475
QTMAN	ZNF592	Q92610	458
QTMAN	MMADHC	Q9H3L0	452
QTMAN	KRTAP13-4	Q3LI77	447
QTMAN	HEATR3	Q7Z4Q2	434
QTMAN	EPC2	Q52LR7	423
QTMAN	ORC4	O43929	423
QTMAN	ZEB2	O60315	393
QTMAN	WWOX	Q9NZC7	381
QTMAN	C2CD2	Q9Y426	372
QTMAN	THSD7B	Q9C0I4	372
QTMAN	KIF5C	O60282	371
QTMAN	FAM47A	Q5JRC9	369

IntAct

0 interactions, top by confidence:

BioGRID (3): GTDC1 (Reconstituted Complex), GTDC1 (Affinity Capture-RNA), APP (Reconstituted Complex)

ESM2 similar proteins: A1JNX9, B0BBT2, B4JLX2, B8DGI9, C1L148, F4HVY0, F4IR05, O06752, O31425, O31656, O31811, O32057, O34703, O34830, O42411, P0ADR8, P0ADR9, P0ADS0, P0ADS1, P0DPS8, P0DPS9, P39612, P39622, P44308, P44898, P50732, P72097, P76361, P94362, P96685, Q04974, Q08DA7, Q17A75, Q21534, Q2G0E1, Q2QEI3, Q3KM61, Q4AE62, Q4L977, Q4V7R4

Diamond homologs: Q08DA7, Q4AE62, Q4V7R4, Q53E76, Q568B7, Q5ZI40, Q66K99, Q8BW56, Q9VXN0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	0
Uncertain significance	36
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
149932	GRCh38/hg38 2q22.3(chr2:144213114-144668146)x1	Pathogenic
441877	GRCh37/hg19 2q22.3(chr2:144796786-145564689)x1	Pathogenic
60213	GRCh38/hg38 2q22.3(chr2:143873711-144513307)x1	Pathogenic
60214	GRCh38/hg38 2q22.3(chr2:143988786-144558029)x1	Pathogenic
60215	GRCh38/hg38 2q22.3(chr2:144164576-144505879)x1	Pathogenic

SpliceAI

4261 predictions. Top by Δscore:

Variant	Effect	Δscore
2:144011671:A:AC	donor_gain	1.0000
2:144011672:C:CC	donor_gain	1.0000
2:144141921:TGGC:T	donor_gain	1.0000
2:144141945:T:A	donor_gain	1.0000
2:144142051:CCAGG:C	acceptor_gain	1.0000
2:144142052:CAGG:C	acceptor_gain	1.0000
2:144142052:CAGGC:C	acceptor_gain	1.0000
2:144142053:AGG:A	acceptor_gain	1.0000
2:144142054:GG:G	acceptor_gain	1.0000
2:144142054:GGCTG:G	acceptor_loss	1.0000
2:144142055:GC:G	acceptor_loss	1.0000
2:144142056:C:CC	acceptor_gain	1.0000
2:144142057:T:C	acceptor_loss	1.0000
2:144145568:CTACC:C	donor_loss	1.0000
2:144145570:A:AC	donor_gain	1.0000
2:144145571:C:CC	donor_gain	1.0000
2:144145611:T:A	donor_gain	1.0000
2:144208614:A:AC	donor_gain	1.0000
2:144208615:C:CC	donor_gain	1.0000
2:144208804:CCTA:C	acceptor_loss	1.0000
2:144208805:C:CC	acceptor_gain	1.0000
2:144208805:CTAA:C	acceptor_loss	1.0000
2:144211513:A:AC	donor_gain	1.0000
2:144211514:C:CC	donor_gain	1.0000
2:144211514:CTT:C	donor_gain	1.0000
2:144211514:CTTCT:C	donor_gain	1.0000
2:144211576:CAAT:C	acceptor_gain	1.0000
2:143952069:TTCAG:T	acceptor_gain	0.9900
2:143952071:CAG:C	acceptor_gain	0.9900
2:143952074:C:CC	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000011880 (2:144276134 A>G), RS1000014900 (2:144016506 G>A,T), RS1000026340 (2:144143083 A>T), RS1000046499 (2:144326494 G>C), RS1000051523 (2:144060084 T>A), RS1000055588 (2:144104602 C>T), RS1000061747 (2:144171867 A>G), RS1000062448 (2:144095924 G>A), RS1000065330 (2:144247169 C>G,T), RS1000069774 (2:143966600 C>T), RS1000081326 (2:144153440 T>C), RS1000085480 (2:144016407 T>C), RS1000093361 (2:144273271 C>T), RS1000096065 (2:144067878 T>C), RS1000116617 (2:144237923 G>A,C)

Disease associations

OMIM: gene MIM:610165 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (2): myoepithelial tumor (MONDO:0002380), neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001762_776	Obesity-related traits	8.000000e-06
GCST003989_19	Chin dimples	4.000000e-15
GCST008491_1	Voxel-wise structural brain imaging measurements in Alzheimer’s disease	5.000000e-07
GCST009438_3	Voxel-wise structural brain imaging measurements in Alzheimer’s disease	3.000000e-06
GCST009597_289	Multiple sclerosis	2.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0003939	energy intake
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009208	Myoepithelioma	C04.557.435.585
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	6
Valproic Acid	affects expression, decreases expression	4
Aflatoxin B1	decreases expression, decreases methylation	3
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation, increases expression	2
Vehicle Emissions	decreases methylation, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
methyleugenol	decreases expression	1
alpha phellandrene	increases expression	1
bisphenol A	decreases methylation	1
trichostatin A	decreases expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
perfluoro-n-nonanoic acid	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Cisplatin	decreases expression, affects cotreatment	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	decreases expression	1
Tobacco Smoke Pollution	increases methylation	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1

Clinical trials (associated diseases)

207 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge